Role of Cardiac Biomarkers and Tomographic Right Ventricular Dysfunction Findings in the Treatment of Pulmonary Thromboembolism
Yazarlar (5)
Maşide Arı T.C. Sağlık Bakanlığı, Türkiye
Dr. Öğr. Üyesi Zeycan Kübra CEVVAL T.C. Sağlık Bakanlığı, Türkiye
Eren Usul
T.C. Sağlık Bakanlığı, Türkiye
T.C. Sağlık Bakanlığı, Türkiye
Emrah Arı
Uğur Kahveci
T.C. Sağlık Bakanlığı
T.C. Sağlık Bakanlığı
| Makale Türü |
Özgün Makale
(ESCI dergilerinde yayınlanan tam makale)
|
||
| Dergi Adı | Eurasian Journal of Emergency Medicine | ||
| Dergi ISSN | 2149-5807 Dergi Bilgileri (2024) | ||
| Dergi Tarandığı Indeksler | ESCI | ||
| Makale Dili | İngilizce | Basım Tarihi | 12-2024 |
| Kabul Tarihi | – | Yayınlanma Tarihi | 22-10-2024 |
| Cilt / Sayı / Sayfa | 23 / 4 / 224–230 | DOI | 10.4274/eajem.galenos.2024.59320 |
| Makale Linki | https://doi.org/10.4274/eajem.galenos.2024.59320 | ||
| UAK Araştırma Alanları |
Radyoloji
|
||
| Özet |
| AimDeaths from acute pulmonary thromboembolism are caused by right ventricular dysfunction (RVD) and often occur within the first hour. Diagnostic computed tomography-pulmonary angiography (CTPA) is a useful tool for the early and rapid evaluation of RVD. We aimed to evaluate the effect of RVD findings on risk classification and treatment.Materials and MethodsThis retrospective study included patients who applied to the emergency department on specified dates and were diagnosed with pulmonary thromboembolism. The right ventricle (RV) and left ventricle (LV) diameters (mm), ratio of these diameters RV/LV, pulmonary artery and aortic diameter (mm), troponin, and BNP were evaluated.ResultsA total of 119 patients were studied. The average age of the participants was 63.3 years. The mortality rate was 12.6%. Reperfusion therapy was applied to 25 (21%) patients. RV/LV was superior for predicting thrombolytic therapy. N-terminal proBNP (NT-proBNP) was more significant than troponin. When both parameters were evaluated together, the result was superior in predicting reperfusion therapy in patients with RVD.ConclusionCTPA can be used safely to determine the risk group and for treatment with its high sensitivity. NT-proBNP is an important biomarker for determining thrombolytic treatment, and its diagnostic specificity increases when evaluated together with RV/LV. |
| Anahtar Kelimeler |
| troponin | pulmonary embolism | BNP | reperfusion therapy | RV/LV | pulmonary artery diameter |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Google Scholar | 2 |